Key facts
- Unravel Biosciences’s last known valuation is $18.0M (Sep 2025).
- It has raised $4.5M across 2 recorded rounds; the latest was Seed Round ($500K) in Feb 2023.
- Notable investors include Creative Destruction Lab, BoxOne Ventures, Solari Capital, Harvard University, Bacchus Venture Capital — 12 tracked in total.
- Unravel Biosciences has filed 2 Form Ds with the SEC since 2021, most recently Mar 2023 ($500K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Unravel Biosciences
Funding rounds
2 roundsAbout Unravel Biosciences
Developer of an artificial intelligence-driven systems biology platform designed to discover and clinically validate therapeutic targets for complex diseases. The company's platform offers Living Molecular Twin modeling, proprietary BioNAV-based computation, and primary transcriptomics-driven disease simulation, enabling biotechnology and pharmaceutical researchers to predict therapeutic response and accelerate data-driven drug discovery and clinical validation.
- Sector
- Healthcare
- HQ
- Medford, MA, United States
- Founded
- 2021
- Employees
- 14
- Website
- unravel.bio/
- Ownership
- Privately Held (backing)
Unravel Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Unravel Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Unravel Biosciences in its N-PORT filings yet. We sweep new filings monthly.